Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or (MPP), technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.
We have applied the MPP technology to create nanosuspensions of loteprednol etabonate, or LE, a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, INVELTYSTM (KPI-121 1.0%) for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. We are also advancing a novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).